1. Home
  2. SNY
  3. SNY News

Latest Sanofi ADS (SNY) News on April 19, 2025

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
SNY

GlobeNewswire

a day ago

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
SNY

GlobeNewswire

a day ago

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
SNY

BioPharma Dive

a day ago

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives

SNY

MT Newswires

2 days ago

Sanofi, Earendil Labs Sign Licensing Deal for Autoimmune, Inflammatory Bowel Disease Treatments

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
SNY

Zacks

2 days ago

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

Sanofi licenses immune disease drugs from startup Earendil
SNY

BioPharma Dive

2 days ago

Sanofi licenses immune disease drugs from startup Earendil

Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY

Zacks

3 days ago

Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
SNY

PR Newswire

4 days ago

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

Tariff wars to hit popular US-made drugs in China, regulator data shows
SNY

Reuters

4 days ago

Tariff wars to hit popular US-made drugs in China, regulator data shows

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
SNY

GlobeNewswire

5 days ago

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Why You Shouldn't Bet Against Sanofi (SNY) Stock
SNY

Zacks

8 days ago

Why You Shouldn't Bet Against Sanofi (SNY) Stock

AAN 2025: Sanofi’s tolebrutinib likely to be first BTK inhibitor for the treatment of MS
SNY

Clinical Trials Arena

10 days ago

AAN 2025: Sanofi’s tolebrutinib likely to be first BTK inhibitor for the treatment of MS

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’
SNY

Bloomberg

10 days ago

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
SNY

GlobeNewswire

11 days ago

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Tariffs Stoke Fears That Hung Debt Will Return
SNY

Bloomberg

14 days ago

Tariffs Stoke Fears That Hung Debt Will Return

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
SNY

Zacks

15 days ago

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
SNY

Pharmaceutical Technology

15 days ago

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions

Sanofi: Information concerning the total number of voting rights and shares - February 2025
SNY

GlobeNewswire

16 days ago

Sanofi: Information concerning the total number of voting rights and shares - February 2025

SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
SNY

Zacks

16 days ago

SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
SNY

Zacks

16 days ago

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
SNY

GlobeNewswire

17 days ago

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Leqembi’s EU review drags on; Sanofi gets a new development head
SNY

BioPharma Dive

17 days ago

Leqembi’s EU review drags on; Sanofi gets a new development head

SNY

MT Newswires

17 days ago

Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?
SNY

Insider Monkey

18 days ago

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
SNY

Zacks

18 days ago

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients
SNY

Pharmaceutical Technology

19 days ago

Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients

FDA Approves Sanofi's Hemophilia Drug
SNY

Benzinga

19 days ago

FDA Approves Sanofi's Hemophilia Drug

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
SNY

GlobeNewswire

22 days ago

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

SNY

MT Newswires

22 days ago

Sanofi Hemophilia Treatment Receives FDA Approval

US FDA approves Sanofi's bleeding disorder therapy
SNY

Reuters

22 days ago

US FDA approves Sanofi's bleeding disorder therapy

FDA approves first-of-its-kind RNA drug for hemophilia
SNY

BioPharma Dive

22 days ago

FDA approves first-of-its-kind RNA drug for hemophilia

SNY

MT Newswires

22 days ago

Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...
SNY

GuruFocus.com

22 days ago

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
SNY

GlobeNewswire

22 days ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
SNY

GlobeNewswire

22 days ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

SNY

Morningstar Research

23 days ago

Analyst Report: Sanofi

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
SNY

Zacks

23 days ago

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive

U.S. to end funding for child vaccines in developing countries, NY Times reports
SNY

TipRanks

23 days ago

U.S. to end funding for child vaccines in developing countries, NY Times reports

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
SNY

Fortune

23 days ago

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate

SNY

Morningstar Research

24 days ago

Analyst Report: Sanofi

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
SNY

Zacks

24 days ago

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
SNY

Pharmaceutical Technology

24 days ago

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
SNY

Zacks

24 days ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
SNY

GlobeNewswire

24 days ago

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
SNY

Zacks

25 days ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
SNY

GlobeNewswire

25 days ago

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Press Release: Availability of the Q1 2025 Aide mémoire
SNY

GlobeNewswire

a month ago

Press Release: Availability of the Q1 2025 Aide mémoire

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
SNY

Zacks

a month ago

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls
SNY

The Fly

a month ago

FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls

Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout
SNY

Bloomberg

a month ago

Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
SNY

Pharmaceutical Technology

a month ago

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody

Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
SNY

Zacks

a month ago

Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease
SNY

BioPharma Dive

a month ago

Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease

SNY

MT Newswires

a month ago

Sanofi to Acquire Dren Bio's Autoimmune Treatment DR-0201 in $600 Million Deal

Sanofi to acquire Dren Bio's immunology unit
SNY

Reuters

a month ago

Sanofi to acquire Dren Bio's immunology unit

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
SNY

GlobeNewswire

a month ago

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Banks Aim to Sell €8.65 Billion Sanofi Buyout Debt Next Week
SNY

Bloomberg

a month ago

Banks Aim to Sell €8.65 Billion Sanofi Buyout Debt Next Week

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
SNY

PR Newswire

a month ago

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
SNY

GlobeNewswire

a month ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
SNY

GlobeNewswire

a month ago

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

CDC plans study into potential vaccines, autism connections, Reuters reports
SNY

TipRanks

a month ago

CDC plans study into potential vaccines, autism connections, Reuters reports

Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
SNY

Zacks

a month ago

Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?

SNY

Morningstar Research

a month ago

Analyst Report: Sanofi

SNY

GlobeNewswire

a month ago

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

What Trump's next batch of tariffs could mean for pharma industry
SNY

Yahoo Finance Video

a month ago

What Trump's next batch of tariffs could mean for pharma industry

SNY

MT Newswires

a month ago

Berenberg Lifts Price Target on Sanofi to EUR120 From EUR115, Keeps Buy Rating

SNY

GuruFocus.com

a month ago

Euroapi SA (EAPIF) (FY 2024) Earnings Call Highlights: Navigating Challenges and Embracing ...

Is Sanofi (SNY) The Best Immunology Stock To Buy Now?
SNY

Insider Monkey

2 months ago

Is Sanofi (SNY) The Best Immunology Stock To Buy Now?

SNY

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Cytokinetics Inc Earnings Call

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...
SNY

GuruFocus.com

2 months ago

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...

Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
SNY

GuruFocus.com

2 months ago

Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...

SNY

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Vir Biotechnology Inc Earnings Call

Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
SNY

Zacks

2 months ago

Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates

Novavax reports large quarterly revenue declines, rethinks its strategic direction
SNY

Yahoo Finance

2 months ago

Novavax reports large quarterly revenue declines, rethinks its strategic direction

SNY

Investing.com

2 months ago

Novavax shares up on fourth quarter earnings beat

Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
SNY

Reuters

2 months ago

Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership

Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MM
SNY

Pharmaceutical Technology

2 months ago

Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MM

SNY

Argus Research

2 months ago

The Argus High-Yield Model Portfolio

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
SNY

GlobeNewswire

2 months ago

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
SNY

Benzinga

2 months ago

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Sanofi, Teva add to case for new bowel disease drug
SNY

BioPharma Dive

2 months ago

Sanofi, Teva add to case for new bowel disease drug

Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
SNY

Clinical Trials Arena

2 months ago

Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
SNY

Zacks

2 months ago

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis

Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
SNY

Insider Monkey

2 months ago

Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
SNY

GlobeNewswire

2 months ago

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
SNY

GlobeNewswire

2 months ago

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
SNY

Zacks

2 months ago

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More

Sanofi moves closer to selling controlling stake in $17bn-valued Opella
SNY

Pharmaceutical Technology

2 months ago

Sanofi moves closer to selling controlling stake in $17bn-valued Opella

Sanofi reaches consumer health deal; Supernus antidepressant fails study
SNY

BioPharma Dive

2 months ago

Sanofi reaches consumer health deal; Supernus antidepressant fails study

Challenges mount for vaccine makers
SNY

Pharma Voice

2 months ago

Challenges mount for vaccine makers

Press Release: Sanofi and CD&R sign Opella share purchase agreement
SNY

GlobeNewswire

2 months ago

Press Release: Sanofi and CD&R sign Opella share purchase agreement

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
SNY

Zacks

2 months ago

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
SNY

Pharmaceutical Technology

2 months ago

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
SNY

GlobeNewswire

2 months ago

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
SNY

Zacks

2 months ago

Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell
SNY

Bloomberg

2 months ago

Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell

SNY

Morningstar Research

2 months ago

Analyst Report: Sanofi

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
SNY

GlobeNewswire

2 months ago

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
SNY

Clinical Trials Arena

2 months ago

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
SNY

Benzinga

2 months ago

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study

Share on Social Networks: